Venrock Adviser, LLC 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Venrock Adviser, LLC disclosed 33 US equity positions worth $3.3bn in its Q2 2026 13F filing. The largest position was APGE at 34.2% of the reported book, followed by ORKA and ERAS. Against the Q1 2026 filing, it opened 4 new positions, added to 5 and reduced 5 among the top 33 holdings.
What did Venrock Adviser, LLC own in Q2 2026? Top 33 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | APGE APOGEE THERAPEUTICS INC | Healthcare | 34.2% | $1.1bn | 8,493,321 | 0% | held |
| 2 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 12.0% | $394.8m | 4,148,428 | 0% | held |
| 3 | ERAS ERASCA INC | Healthcare | 9.9% | $327.8m | 17,891,812 | 9% | added |
| 4 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 8.0% | $265.0m | 2,985,448 | -19% | reduced |
| 5 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 3.5% | $115.0m | 1,180,000 | 0% | held |
| 6 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 3.1% | $101.6m | 10,346,926 | 0% | held |
| 7 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 2.8% | $93.7m | 3,603,595 | 0% | held |
| 8 | SVRA SAVARA INC | Healthcare | 2.8% | $90.8m | 14,745,943 | 7% | added |
| 9 | JBIO JADE BIOSCIENCES INC | Healthcare | 2.2% | $71.6m | 3,220,364 | 0% | held |
| 10 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.9% | $63.6m | 1,642,166 | -18% | reduced |
| 11 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 1.8% | $59.8m | 3,257,917 | -16% | reduced |
| 12 | VOR VOR BIOPHARMA INC | Healthcare | 1.7% | $56.0m | 3,041,719 | 0% | held |
| 13 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.5% | $48.3m | 2,173,913 | 0% | held |
| 14 | MAZE MAZE THERAPEUTICS INC | Healthcare | 1.4% | $47.8m | 1,602,034 | 0% | held |
| 15 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 1.4% | $47.4m | 6,844,305 | 41% | added |
| 16 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.4% | $46.8m | 4,319,765 | 0% | held |
| 17 | CBIO CRESCENT BIOPHARMA INC. | 1.2% | $38.4m | 2,133,576 | 0% | held | |
| 18 | ZURA ZURA BIO LTD | Healthcare | 1.2% | $38.0m | 6,434,990 | 0% | held |
| 19 | ANL ADLAI NORTYE LTD | 1.1% | $36.9m | 3,212,731 | 0% | held | |
| 20 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.8% | $26.7m | 526,331 | -70% | reduced |
| 21 | HELP CYBIN INC | 0.8% | $25.5m | 3,851,654 | 0% | held | |
| 22 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 0.8% | $25.1m | 1,379,965 | 0% | held |
| 23 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.6% | $21.3m | 8,695,652 | 0% | held |
| 24 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.6% | $19.8m | 2,043,596 | 27% | added | |
| 25 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 0.6% | $18.7m | 4,982,124 | -50% | reduced |
| 26 | ACHV ACHIEVE LIFE SCIENCE INC | 0.5% | $18.0m | 2,751,032 | – | new | |
| 27 | PARABILIS MEDICINES INC | 0.5% | $17.1m | 625,000 | – | new | |
| 28 | SRZN SURROZEN INC | 0.5% | $16.4m | 632,931 | 0% | held | |
| 29 | KRRO KORRO BIO INC | Healthcare | 0.4% | $13.3m | 1,009,500 | 0% | held |
| 30 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 0.4% | $13.2m | 500,000 | 0% | held |
| 31 | XFOR X4 PHARMACEUTICALS INC | 0.3% | $9.0m | 1,934,253 | 485% | added | |
| 32 | RESEARCH ALLIANCE CORP III | 0.1% | $3.2m | 300,000 | – | new | |
| 33 | INM INMED PHARMACEUTICALS INC | 0.0% | $50.7k | 32,685 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.